Skip to content
  • Mediacenter
  • Literature Database
  • Investor News
  • Careers
  • Get in Contact
International (English)
Locale
CytoSorbents Europe GmbH
International (English)
Locale
Hotline
  • The Therapy
    • Background
    • Fields of application for the CytoSorb Therapy
    • Ticagrelor and Rivaroxaban
    • Therapeutic aspects
    • COVID-19
    • Global decision support
    • Product safety
    • Testimonials
  • CytoScore
  • The Studies
    • Multicenter Studies
    • Monocenter studies
    • The CytoSorb-Registry
    • Case of the Month Submission
  • The Adsorber
    • Setup of CytoSorb
    • Usage and Application
    • Technical data
    • Q&A
  • Events
  • Support
    • Mediacenter
    • Reimbursement & Coding of CytoSorb Therapy
    • Newsletter Registration
    • Hotline
  • About us
    • Corporation Management
    • CytoSorbents worldwide
    • Scientific partners
    • 10 Years CytoSorb® Therapy
    • Careers
    • Get in Contact

New data on anti-infective agents removal by CytoSorb | German voice over

Current knowledge and how we can use it in daily routine | German voice over

Drug removal with CytoSorb hemoadsorption – do we face more Pros than Cons? | INTERNATIONAL EXPERTS MEETING | Critical Care Webinar 3 | German voice over

Best Bits | International Expert Meeting | Intensive Care | Mathias Stroehle

Best Bits | International Expert Meeting | Intensive Care | Klaus Kogelmann

Septic shock and shock reversal – can CytoSorb therapy make a difference? | INTERNATIONAL EXPERTS MEETING | Critical Care Webinar 2 | English

Septic shock and shock reversal – can CytoSorb therapy make a difference? | INTERNATIONAL EXPERTS MEETING | Critical Care Webinar 2 | German voice over

Choque séptico y reversión del choque: ¿puede el tratamiento con CytoSorb marcar la diferencia? | REUNIÓN DE EXPERTOS INTERNACIONALES | CUIDADOS INTENSIVOS Webinar No. 2

Hemoadsorption in septic shock reduces catecholamine requirements and in hospital mortality – results of a retrospective single center trial

Hemoadsorption in septic shock reduces catecholamine requirements and in hospital mortality – results of a retrospective single center trial

  • Previous
  • 1
  • 2
  • 3
  • 4
  • ...
  • 9
  • Next
CytoSorbents Europe GmbH
Facebook-f Twitter Linkedin Youtube

CytoSorbents Europe GmbH
Müggelseedamm 131
12587 Berlin

support(at)cytosorbents.com

©2023 CYTOSORBENTS EUROPE GMBH | ALL RIGHTS RESERVED

*CytoSorb Therapy is the use of the CytoSorb adsorber in conditions where elevated levels of Cytokines and/or Bilirubin and/or Myoglobin exist. CytoSorb can also be used intraoperatively for the removal of Ticagrelor and/or Rivaroxaban during Cardiopulmonary-Bypass.

  • Privacy Information
  • Data protection
  • Disclaimer
  • Imprint
CytoSorbents Europe GmbH
  • The Therapy
    • Background
    • Fields of application for the CytoSorb Therapy
    • Ticagrelor and Rivaroxaban
    • Therapeutic aspects
    • COVID-19
    • Global decision support
    • Product safety
    • Testimonials
  • CytoScore
  • The Studies
    • Multicenter Studies
    • Monocenter studies
    • The CytoSorb-Registry
    • Case of the Month Submission
  • The Adsorber
    • Setup of CytoSorb
    • Usage and Application
    • Technical data
    • Q&A
  • Events
  • Support
    • Mediacenter
    • Reimbursement & Coding of CytoSorb Therapy
    • Newsletter Registration
    • Hotline
  • About us
    • Corporation Management
    • CytoSorbents worldwide
    • Scientific partners
    • 10 Years CytoSorb® Therapy
    • Careers
    • Get in Contact
APPLY TODAY
JOBS
International (English)
  • Privacy Policy
  • Data protection
  • Disclaimer
  • Imprint